Literature DB >> 8084395

Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report.

A Silvani1, A Salmaggi, G Parmiani, A Boiardi.   

Abstract

We report the case of a girl who developed cerebellar medulloblastoma at the age of 12 years and in whom, 4 years after surgical removal and radiotherapy, neoplastic dissemination via the cerebrospinal fluid took place. After only partially effective systemic and intrathecal chemotherapy, an intrathecal administration of lymphokine-activated killer cells and recombinant interleukin-2 allowed complete clinical recovery persisting after a follow-up of 30 months.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8084395     DOI: 10.1227/00006123-199406000-00021

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  4 in total

1.  Soluble factors, including TNF alpha, secreted by human T cells are both cytotoxic and cytostatic for medulloblastoma cells.

Authors:  N Dufay; A Reboul; F Touraine-Moulin; M F Belin; P Giraudon
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

Review 2.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

3.  In vitro Natural Killer Cell Immunotherapy for Medulloblastoma.

Authors:  Lucia Fernández; Raquel Portugal; Jaime Valentín; Roberto Martín; Hannah Maxwell; Marta González-Vicent; Miguel Ángel Díaz; Inmaculada de Prada; Antonio Pérez-Martínez
Journal:  Front Oncol       Date:  2013-04-19       Impact factor: 6.244

4.  Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma.

Authors:  Jeroen F Vermeulen; Wim Van Hecke; Elisabeth J M Adriaansen; Mieke K Jansen; Rianne G Bouma; José Villacorta Hidalgo; Paul Fisch; Roel Broekhuizen; Wim G M Spliet; Marcel Kool; Niels Bovenschen
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.